

## LIBERIA

### Support for Measles Containing Vaccine

This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b> Liberia							
<b>2. Vaccine grant number:</b>		19-LBR-08n-Y, 1920-LBR-09b-X					
<b>3. Date of Decision Letter:</b>		30-Sep-2019					
<b>4. Date of the Partnership Framework Agreement:</b>		19 August 2013					
<b>5. Programme title:</b>		New Vaccine Support (NVS), Measles, 2D Routine					
<b>6. Vaccine type:</b>		Measles					
<b>7. Requested product presentation and formulation of vaccine:</b> Measles, 10 doses per vial, LYOPHILISED							
<b>8. Programme Duration:</b> <sup>1</sup> 2019-2020							
<b>9. Programme Budget (indicative):</b> <sup>2</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)							
	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>2024</b>	<b>Total</b> <sup>2</sup>
Programme Budget (US\$)	40,500	67,500	-	-	-	-	108,000
<b>10. Vaccine introduction grant</b>							
<b>Approval</b>							
<b>Year</b>	<b>Grant Number</b>			<b>Amount (US\$)</b>			
2019	19-LBR-08n-Y			153,469			
<b>Disbursement</b>							
<b>Disbursement date</b>				<b>Amount (US\$)</b>			
17 January, 2019				150,400			
<b>11. Product switch grant</b>							
Not applicable							
<b>12. Indicative Annual Amounts:</b> <sup>3</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)							
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>				

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Number of vaccine doses		224,400	-
Annual Amounts (US\$)	40,500	67,500	-

**13. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**14. Self-procurement:** Not applicable

**15. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	453,600	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	130,174	-	-	-	-
Total co-financing payments (US\$) (including freight)	136,000	-	-	-	-
Minimum number of doses to be financed from domestic resources	356,842	-	-	-	-
Minimum amount to be financed from domestic resources (US\$)	169,301	-	-	-	-

In order to mitigate risks of stocking out in 2020, co-financing obligation associated with this program should be fulfilled by May 2020.

**16. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
<ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> </ul>	31 March 2020
<ul style="list-style-type: none"> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	15 May 2020

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
---	------------------------------------

<b>17. Financial clarifications:</b>	Not applicable
--------------------------------------	----------------

Signed by,  
**On behalf of Gavi**



Thabani Maphosa,  
Managing Director, Country Programmes  
30-Sep-2019